Cohance Lifesciences Ltd

Cohance Lifesciences Limited held its Q1 FY27 earnings conference call on August 5, 2026, where management reported that the quarter was the lowest in their history, as previously indicated. They anticipated improvement in Q2 FY27 and a return to year-on-year growth in the second half of the fiscal year, supported by scheduled deliveries and improved operational utilization. Management highlighted progress in their nucleic acid business and specialty chemicals, with a focus on integrating capabilities and enhancing customer relationships. The company reported a 38.7% year-on-year decline in Pharma CDMO revenue due to shipment timing, but noted strong operational delivery and customer audits without critical findings. Consolidated revenue was INR 4,223 million, a 23% decline year-on-year, with a gross margin of 71.5%. Management expressed confidence in the recovery trajectory, citing strong customer relationships and scientific capabilities as key growth drivers.

The document presented both challenges faced in Q1 and management's confidence in future recovery.